VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

Research analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRXGet Rating) in a research note issued to investors on Thursday. The firm set a “sell” rating on the stock.

VolitionRx Price Performance

VNRX opened at $1.54 on Thursday. VolitionRx has a 1 year low of $1.31 and a 1 year high of $3.30.

About VolitionRx

(Get Rating)

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Featured Stories

Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.